Systemic Therapy for Advanced Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer

Clinicians should recommend HER2-targeted therapy-based combinations for first-line treatment, except for highly selected patients with estrogen receptor-positive (ER+) or progesterone receptor-positive (PgR+) and HER2-positive disease for whom clinicians may use endocrine therapy alone. (EB, , H, S)